


FORM PTO-1390 (REV. 7-2005)		U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	ATTORNEY'S DOCKET NUMBER <b>P/4043-258</b>
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371</b>		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>10/567238</b>	
INTERNATIONAL APPLICATION NO. <b>PCT/ES2004/000361</b>	INTERNATIONAL FILING DATE <b>4 August 2004</b>	PRIORITY DATE CLAIMED <b>4 August 2003</b>	
TITLE OF INVENTION <b>COMPOUNDS FOR THE TREATMENT OF DEMYELINATING AND AUTOIMMUNE DISEASES</b>			
APPLICANT(S) FOR DO/EO/US <b>Carlos MATUTE ALMAU et al.</b>			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a submission under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</li> <li>4. <input checked="" type="checkbox"/> The US has been elected (Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))             <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).             <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))             <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input checked="" type="checkbox"/> An <b>executed</b> oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li>10. <input checked="" type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>			
Items 11 to 20 below concern other document(s) or information included:			
<ol style="list-style-type: none"> <li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input type="checkbox"/> A preliminary amendment.</li> <li>14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76</li> <li>15. <input type="checkbox"/> A substitute specification.</li> <li>16. <input type="checkbox"/> A power of attorney and/or change of address letter.</li> <li>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.</li> <li>18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</li> <li>19. <input type="checkbox"/> A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).</li> </ol>			
<b>EXPRESS MAIL CERTIFICATE</b>			
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee (mail label #EV343679155US) in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 223131450, on February 3, 2006 :			
Dorothy Jenkins Name of Person Mailing Correspondence		 Signature	
		<u>February 3, 2006</u> Date of Signature	


U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>10/567238</b>	INTERNATIONAL APPLICATION NO. <b>PCT/ES2004/000361</b>	ATTORNEY'S DOCKET NUMBER <b>P/4043-258</b>		
20. [X] 9 Sheet of Drawings; EFS Form: postcard; Copy of 1 <sup>st</sup> page of publication; International Search Report, PTO-1449 with 8 References, English Translations to the IPER Claims.				
The following fees have been submitted				
21. [X] Basic national fee (37 CFR 1.492(a)).....\$300				
\$300.00				
22. [X] Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4).....\$0				
\$200.00				
All other situations.....\$200				
23. [X] Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4).....\$0				
\$400.00				
Search fee (37 CFR 1.445(a)(2) has been paid on the international application to the USPTO as an International Searching Authority.....\$100				
International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB.....\$400				
All other situations.....\$500				
<b>TOTAL OF 21, 22 and 23 =</b>				
\$900.00				
[ ] Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.				
Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)		
		x \$250		
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).				
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total Claims	6 - 20 =		x \$ 50	\$
Independent Claims	3 - 3 =		x \$200	\$
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360	\$
<b>TOTAL OF ABOVE CALCULATIONS =</b>			\$900.00	
[ X] Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.				
<b>SUBTOTAL =</b>			\$450.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).			\$	
<b>TOTAL NATIONAL FEE =</b>			\$450.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by the appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$40.00	
<b>TOTAL FEES ENCLOSED =</b>			\$490.00	
			Amount to be refunded:	\$
			Amount to be charged:	\$

a.  A check (check number 23465) in the amount of \$490.00 to cover the above fees is enclosed.  
 b.  Please charge my Deposit Account No. 15-0700 in the amount of \$ to cover the above fees.  
 A duplicate copy of this sheet is enclosed.  
 c.  The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 15-0700. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.

SEND ALL CORRESPONDENCE TO:

Mark A. Farley, Esq.  
 OSTROLENK, FABER, GERB & SOFFEN, LLP  
 1180 Avenue of the Americas  
 New York, New York 10036-8402  
 Telephone: (212) 382-0700

  
 SIGNATURE  
Mark A. Farley  
 NAME  
33,170  
 REGISTRATION NUMBER